SOMA (carisoprodol) by Viatris (2) is identified. First approved in 1959.
Drug data last refreshed 2d ago · AI intelligence enriched 4w ago
SOMA (carisoprodol) is an oral muscle relaxant approved in 1959 that works by altering interneuronal activity in the spinal cord and descending reticular formation to reduce muscle tension. It is indicated for acute musculoskeletal pain and is administered as an oral capsule.
Product is approaching loss of exclusivity with minimal Part D volume (1,605 claims in 2023), indicating a mature, declining asset with limited commercial infrastructure.
identified. In animal studies, muscle relaxation induced by carisoprodol is associated with altered interneuronal activity in the spinal cord and in the descending reticular formation of the brain.
Muscle Relaxant
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)
Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency
SOMA Validation RCT: Testing Structural Equivalence and Mechanistic Orthogonality of an Open-Source Mindfulness Stimulus Library
TENS for Restoring Somatotopic Sensory Feedback in Lower Limb Amputees and Improving Phantom Limb Perception
Worked on SOMA at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moViatris (2) is hiring 4 roles related to this product
Only one linked job posting found (engineering-focused), reflecting minimal active career development around SOMA at parent company Viatris. The product's mature status and approaching LOE make it a low-priority assignment for most commercial and medical functions.
1 open roles linked to this drug